FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway

Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway

(2017) Ting-ting Wang et al.   GUT

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

(2017) Matthew A. Coelho et al.   IMMUNITY

FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1

(2017) Tingting Huang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

(2017) Arjun V Balar et al.   LANCET

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Tumour CD274 (PD-L1) expression and T cells in colorectal cancer

(2016) Yohei Masugi et al.   GUT

PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes

(2016) Matthew W Rosenbaum et al.   MODERN PATHOLOGY

Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer

(2016) Yaqi Li et al.   Molecular Cancer

Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution

(2016) Yun-Hee Youm et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

PD-1/PD-L1 inhibitors

(2015) Joel Sunshine et al.   CURRENT OPINION IN PHARMACOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence

(2015) Christina Giannopoulou et al.   PHARMACOECONOMICS

Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction

(2015) Edward P. Carter et al.   TRENDS IN CELL BIOLOGY

Colorectal cancer

(2015) Ernst J. Kuipers et al.   Nature Reviews Disease Primers

Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis

(2014) Tinghong Ye et al.   BREAST CANCER RESEARCH AND TREATMENT

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity

(2014) Suzanne Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer

(2013) Minmin Song et al.   PLoS One

B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells

(2013) Sheng-Jia Shi et al.   PLoS One

FGFR2 gene amplification and clinicopathological features in gastric cancer

(2012) K Matsumoto et al.   BRITISH JOURNAL OF CANCER

Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

(2012) D. S. Chen et al.   CLINICAL CANCER RESEARCH

Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer Cells

(2012) Y. Matsuda et al.   MOLECULAR CANCER THERAPEUTICS

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anticancer molecules targeting fibroblast growth factor receptors

(2012) Guang Liang et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Overexpressed fibroblast growth factor receptor 2 in the invasive front of colorectal cancer: A potential therapeutic target in colorectal cancer

(2011) Yoko Matsuda et al.   CANCER LETTERS

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

Signal Transducers and Activators of Transcription-3 Binding to the Fibroblast Growth Factor Receptor Is Activated by Receptor Amplification

(2010) A. A. Dudka et al.   CANCER RESEARCH

Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma

(2009) Michael G. Gartside et al.   MOLECULAR CANCER RESEARCH

De-regulated FGF receptors as therapeutic targets in cancer

(2009) Victoria Knights et al.   PHARMACOLOGY & THERAPEUTICS

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology